1. Most Discussed
  2. Gainers & Losers
SIE 6.8¢

worthy of interest

  1. floyds

    2,830 Posts.

    Biotech bubble too good to be true
    Geoffrey Newman
    September 17, 2003

    IT could be time to cash in on the run in biotechnology stocks, according to broker Tolhurst Noall, which yesterday warned investors the sector was in danger of collapse, driven more by sentiment than fundamentals.

    A Tolhurst report warned investors that the large price rises in many biotech stocks could evaporate as quickly as they had appeared.

    "Most of the sector is driven by sentiment first and fundamentals second," said Tolhurst broker Marcus Padley.

    "Make no mistake, when the market goes down, this sector is going to get caned. It is full of traders and profits."

    The biotech sector has risen by about 25 per cent since May as a general recovery in the stock market encouraged investors to take on more risk in exchange for potentially higher returns if these technologies - many still yet to progress beyond the lab - proved a success. It has also been a magnet for day traders attempting to profit from volatile price movements.

    Some stocks, like pharmaceutical company Chemeq, have doubled or tripled in price in recent months.

    But some of the fundamentals that have underpinned the stock market's recovery are under question. The bourse has fallen from its 13-month highs of last week as investors questioned the strength of the US economic recovery following a string of disappointing data.

    Tolhurst has picked just 15 stocks out of about 70 whose technologies are worthy of interest - only three of which are recommended as a "buy".

    "It is time to take a good look at the sector and decide whether you have an 'investment' on your hands or just a stock that has been in the right place for the last three months that you should take a profit on," Mr Padley said.

    The chosen stocks are anti-fat drug maker Metabolic, Chemeq, Agenix, anti-cancer researcher Peplin Biotech, Benitec, Epitan, Meditech Research, Scigen, Prima Biomed, Psiron, Circadian Technologies, Axon Instruments and Medical Monitors, e-health business Pro Medicus and Vital Capital.

    "These stocks tend to run a bit ahead of themselves," said ABN Amro biotech analyst Scott Power. "But there are a number of companies which do offer some reasonable upside." He nominated Agenix, heart-pump developer Ventracor, Metabolic, Peplin Biotech and Medica Holdings as the picks of the sector.

    The Australian

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.